Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GNOS-PV02, INO-9012, and Pembrolizumab in Advanced Hepatocellular Carcinoma
NCT04251117Phase 2Active, not recruiting
- Sponsor
- Geneos Therapeutics
- Start
- Mar 2020
- Primary completion
- Nov 2024
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of GNOS-PV02 in hepatocellular carcinoma (HCC), sponsored by Geneos Therapeutics. Primary endpoints: Incidence of Treatment-Related Adverse Events at 57 months, Neoantigen-Specific T-Cell Response at 12 weeks and 1 more. Started Mar 2020; status: active, not recruiting.
02
Drugs
GNOS-PV02
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04251117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04251117.